On the other hand, the major strength of our study was evaluation of a prospective large cohort of IBD and ITB patients for FOXP3+ T cell expression in both blood and colonic mucosa and further use of this information for identifying FOXP3 as an immunological biomarker to differentiate ITB from CD. Here, FOXP3 is linked to inflammatory bowel disease.